Malignant lymphoma
Conditions
Interventions
None listed
Sponsors
Hirotaka Nakamura
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [Study Subjects for Medical Record Review] (1) Inclusion Criteria Patients with malignant lymphoma who received outpatient chemotherapy at our hospital between December 2022 and September 30, 2025, underwent primary prophylaxis for febrile neutropenia (FN), and received at least one administration of OBI or PFS. Patients who were considered adults under the Civil Code at the time of obtaining informed consent for primary FN prophylaxis. [Study Subjects for Questionnaire Survey] (1) Inclusion Criteria Patients with malignant lymphoma who received outpatient chemotherapy at our hospital between December 2022 and September 30, 2025, underwent primary prophylaxis for FN, and used OBI between the date of study approval and August 30, 2026. Patients who were considered adults under the Civil Code at the time informed consent was obtained.
Exclusion criteria
Exclusion criteria: [Study Subjects for Medical Record Review] (2) Exclusion Criteria Patients who initiated primary prophylaxis from a later cycle rather than from the first cycle of outpatient chemotherapy. Patients whose treatment was switched from OBI to PFS, or from PFS to OBI, during the course of outpatient chemotherapy. [Study Subjects for Questionnaire Survey] (2) Exclusion Criteria Patients who initiated primary prophylaxis from a later cycle rather than from the first cycle of outpatient chemotherapy. Patients whose treatment was switched from OBI to PFS, or from PFS to OBI, during the course of outpatient chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of FN | — |
Contacts
Public ContactNakamura Hirotaka
National Cancer Center Hospital East
Outcome results
None listed